UK markets close in 2 hours 37 minutes
  • FTSE 100

    7,343.31
    +84.99 (+1.17%)
     
  • FTSE 250

    19,390.70
    +71.75 (+0.37%)
     
  • AIM

    909.45
    +5.96 (+0.66%)
     
  • GBP/EUR

    1.1595
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2227
    -0.0044 (-0.35%)
     
  • BTC-GBP

    17,172.54
    -252.66 (-1.45%)
     
  • CMC Crypto 200

    459.14
    -2.66 (-0.58%)
     
  • S&P 500

    3,900.11
    -11.63 (-0.30%)
     
  • DOW

    31,438.26
    -62.42 (-0.20%)
     
  • CRUDE OIL

    110.99
    +1.42 (+1.30%)
     
  • GOLD FUTURES

    1,824.60
    -0.20 (-0.01%)
     
  • NIKKEI 225

    27,049.47
    +178.20 (+0.66%)
     
  • HANG SENG

    22,418.97
    +189.45 (+0.85%)
     
  • DAX

    13,265.73
    +79.66 (+0.60%)
     
  • CAC 40

    6,109.33
    +62.02 (+1.03%)
     

Bavarian Nordic raises 2022 annual guidance again after monkeypox vaccine deals

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: A laboratory of the vaccine company Bavarian Nordic, in Martinsried near Munich
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Danish biotechnology company Bavarian Nordic revised its annual guidance on Monday for a second time after signing supply contracts with several undisclosed countries for its Imvanex monkeypox vaccine.

Bavarian Nordic said vaccine deliveries would start immediately and added that it was in discussions with more countries regarding vaccine supply.

"We are pleased to assist more countries with supply of vaccines while we continue our dialogues with other governments to make vaccines available as fast as possible to mitigate the situation," CEO Paul Chaplin said in a statement.

Bavarian now expects 2022 revenue to be between 1.4 billion and 1.5 billion Danish crowns ($202.93 million and $217.43 million), up from earlier estimates of 1.3 billion to 1.5 billion.

The company also lifted its expectations for earnings before interest, tax and amortisation (EBITDA) to a loss of between 900 million and 1.1 billion crowns, up from previous guidance of loss of between 1 billion and 1.2 billion crowns.

Monkeypox is an infectious disease that is usually mild and is endemic in parts of west and central Africa. Global health officials have tracked more than 200 suspected and confirmed cases of the viral infection in 19 countries since early May.

The European Union last week announced that it was in talks to buy Bavarian Nordic's vaccine. The vaccine has official European approval for smallpox, although doctors can prescribe it off-label for monkeypox.

(Reporting by Ann Maria Shibu in Bengaluru; Editing by Nick Macfie)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting